公开(公告)号：EP2590630B1

公开(公告)日：2015-04-29

申请号：EP11731268.6

申请日：2011-07-07

申请人： ratiopharm GmbH

发明人： PAETZ, Jana ,  RIMKUS, Katrin

IPC分类号： A61K9/20 ,  A61J3/10 ,  A61K9/00 ,  A61K9/10 ,  A61K31/4196

CPC分类号： A61K31/4196 ,  A61J3/10 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2095

公开(公告)号：EP2590630A1

公开(公告)日：2013-05-15

申请号：EP11731268.6

申请日：2011-07-07

申请人： Ratiopharm GmbH

发明人： PAETZ, Jana ,  RIMKUS, Katrin

IPC分类号： A61K9/20 ,  A61J3/10 ,  A61K9/00 ,  A61K9/10 ,  A61K31/4196

CPC分类号： A61K31/4196 ,  A61J3/10 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2095

摘要： The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it.

公开(公告)号：EP2585050A1

公开(公告)日：2013-05-01

申请号：EP11727468.8

申请日：2011-06-27

申请人： Ratiopharm GmbH

发明人： RIMKUS, Katrin ,  STEFAN, Ralph

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K31/4045

CPC分类号： A61K9/1652 ,  A61K9/1635 ,  A61K9/2027 ,  A61K9/2054 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0015

摘要： The invention relates to a process for the preparation of a pharmaceutical with an inclusion compound of the active substance silodosin or a pharmaceutically acceptable salt thereof and a cyclodextrin, comprising the process step: a) silodosin or a pharmaceutically acceptable salt thereof is brought into contact with a cyclodextrin in the presence of a solvent, giving rise to a silodosin-cyclodextrin inclusion compound; b) the silodosin-cyclodextrin inclusion compound of step a) is mixed with one or more pharmaceutically acceptable additives; c) drying of the product of step a) and/or step b); and d) if appropriate, the dried mixture is optionally further processed with further pharmaceutically acceptable additives to give a unit dose form.

公开(公告)号：EP2416761A1

公开(公告)日：2012-02-15

申请号：EP10720884.5

申请日：2010-05-10

申请人： Ratiopharm GmbH

发明人： FISCHER, Dirk ,  KOELLNER, Gertraud ,  AUER, Gertrud ,  RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PAETZ, Jana

IPC分类号： A61K9/14 ,  A61K31/137 ,  A61P31/10

CPC分类号： C07C215/54 ,  A61K9/2081 ,  A61K9/2866 ,  A61K9/5047 ,  A61K31/137 ,  C07B2200/07 ,  C07C59/255

摘要： The invention relates to desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic "form R", and to a process for the production thereof. In a second aspect, the invention relates to the desfesoterodine according to the invention in micro-encapsulated form.

公开(公告)号：EP2408431A1

公开(公告)日：2012-01-25

申请号：EP10709698.4

申请日：2010-03-17

申请人： Ratiopharm GmbH

发明人： RIMKUS, Katrin ,  PÄTZ, Jana

IPC分类号： A61K9/16 ,  A61K9/19 ,  A61K31/167

CPC分类号： A61K31/167 ,  A61K9/146 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/19 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/27

摘要： The invention relates to solid retigabine in non-crystalline form together with a surface stabilizator in form of a stable intermediate. In the intermediate according to the invention, retigabine is preferably present in amorphous form or in the form of a solid solution. The invention further relates to methods for producing retigabine in solid, non-crystalline form and to pharmaceutical formulations, containing solid, non-crystalline retigabine.

公开(公告)号：EP2178507B1

公开(公告)日：2019-05-15

申请号：EP08785000.4

申请日：2008-07-23

申请人： ratiopharm GmbH

发明人： ALLES, Rainer ,  KOTSCHENREUTHER, Dunja ,  KOELLNER, Gertraud ,  RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PAETZ, Jana

IPC分类号： A61K9/16 ,  A61K9/20

公开(公告)号：EP2877162A1

公开(公告)日：2015-06-03

申请号：EP13740041.2

申请日：2013-07-25

申请人： ratiopharm GmbH

发明人： STEFAN, Ralph ,  SIEVERT, Frank ,  RIMKUS, Katrin

IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K31/4045 ,  A61K31/519

CPC分类号： A61K31/519 ,  A61J3/005 ,  A61J3/10 ,  A61K9/0004 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/28 ,  A61K9/2866

摘要： The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms.

公开(公告)号：EP2416761B1

公开(公告)日：2015-02-11

申请号：EP10720884.5

申请日：2010-05-10

申请人： ratiopharm GmbH

发明人： FISCHER, Dirk ,  KOELLNER, Gertraud ,  AUER, Gertrud ,  RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PAETZ, Jana

IPC分类号： A61K9/14 ,  A61K31/137 ,  A61P31/10 ,  A61K9/26 ,  A61K9/50 ,  C07C215/54 ,  C07C59/255

CPC分类号： C07C215/54 ,  A61K9/2081 ,  A61K9/2866 ,  A61K9/5047 ,  A61K31/137 ,  C07B2200/07 ,  C07C59/255

公开(公告)号：EP2408424A2

公开(公告)日：2012-01-25

申请号：EP10711009.0

申请日：2010-03-17

申请人： Ratiopharm GmbH

发明人： PAETZ, Jana ,  RIMKUS, Katrin

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K31/27 ,  A61K9/16

CPC分类号： A61K31/27 ,  A61K9/0007 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095

摘要： The invention relates to dry processing methods for producing oral dosage forms, in particular tablets, containing retigabine and adhesion promoters. The invention further relates to compacted intermediates, containing retigabine and an adhesion promoter. Finally, the invention relates to single and multiple dose containers, preferably sachets and stick packs, containing the intermediate according to the present invention.

公开(公告)号：EP2320901A1

公开(公告)日：2011-05-18

申请号：EP09782126.8

申请日：2009-08-24

申请人： Ratiopharm GmbH

发明人： RIMKUS, Katrin ,  MUSKULUS, Frank ,  BRUECK, Sandra ,  PÄTZ, Jana

IPC分类号： A61K31/517

CPC分类号： A61K9/2054

摘要： The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition.